ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
A Study to Evaluate the Safety and Efficacy of FK506E (MR4) in Patients Undergoing Primary Liver Transplantation.
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2014-07-09
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 475
- Registration Number
- NCT00189826
A Study to Evaluate the Safety and Efficacy of FK506E (MR4) in Patients Undergoing Primary Kidney Transplantation
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2014-07-09
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 699
- Registration Number
- NCT00189839
Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia
Phase 3
Completed
- Conditions
- CandidemiaInvasive Candidiasis
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2008-01-02
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT00189709
Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
Phase 3
Completed
- Conditions
- Irritable Bowel Syndrome
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Astellas Pharma Inc
- Registration Number
- NCT00189696
Community Based Trial for AMEVIVE®
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2014-09-08
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 114
- Registration Number
- NCT00168753
- Locations
- 🇺🇸
Michael Scannon, Tampa, Florida, United States
🇺🇸Calumet Dermatology Associates, Calumet City, Illinois, United States
🇺🇸Skin and Cancer Associates, Tamarac, Florida, United States
Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens
Phase 3
Completed
- Conditions
- Heart DiseasesHeart Transplantation
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 111
- Registration Number
- NCT00157014
Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease
Phase 2
Completed
- Conditions
- Gastroesophageal Reflux
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2011-11-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 480
- Registration Number
- NCT00141960
Effect of Rapid Steroid Withdrawal on Subclinical Markers of Rejection
Phase 4
Terminated
- Conditions
- Kidney Transplantation
- Interventions
- First Posted Date
- 2005-08-23
- Last Posted Date
- 2014-09-08
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 85
- Registration Number
- NCT00133172
Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery
Phase 3
Completed
- Conditions
- Atrial FlutterAtrial Fibrillation
- First Posted Date
- 2005-08-01
- Last Posted Date
- 2007-12-24
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 190
- Registration Number
- NCT00125320
A Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma
Phase 2
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-06-28
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Astellas Pharma Inc
- Registration Number
- NCT00116103
© Copyright 2025. All Rights Reserved by MedPath